Global Anti-Obesity Prescription Drugs Market Insights, Forecast to 2025

2 Global Anti-Obesity Prescription Drugs Quarterly Market Size Analysis

• 2.1 Anti-Obesity Prescription Drugs Business Impact Assessment - COVID-19
  • 2.1.1 Global Anti-Obesity Prescription Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Anti-Obesity Prescription Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Anti-Obesity Prescription Drugs Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Anti-Obesity Prescription Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Anti-Obesity Prescription Drugs Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Anti-Obesity Prescription Drugs Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Anti-Obesity Prescription Drugs Market
• 3.5 Key Manufacturers Anti-Obesity Prescription Drugs Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Anti-Obesity Prescription Drugs Segments, By Type

• 4.1 Introduction
  • 1.4.1 Orlistat
  • 1.4.2 Phentermine and Topiramate
  • 1.4.3 Bupropion and Naltrexone
  • 1.4.4 Lorcaserin
  • 1.4.5 Liraglutide
• 4.2 By Type, Global Anti-Obesity Prescription Drugs Market Size, 2019-2021
  • 4.2.1 By Type, Global Anti-Obesity Prescription Drugs Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Anti-Obesity Prescription Drugs Price, 2020-2021

5 Impact of Covid-19 on Anti-Obesity Prescription Drugs Segments, By Application

• 5.1 Overview
  • 5.5.1 Pediatric
  • 5.5.2 Adult
• 5.2 By Application, Global Anti-Obesity Prescription Drugs Market Size, 2019-2021
  • 5.2.1 By Application, Global Anti-Obesity Prescription Drugs Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Anti-Obesity Prescription Drugs Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 F Hoffmann La Roche Ltd
  • 7.1.1 F Hoffmann La Roche Ltd Business Overview
  • 7.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020
  • 7.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Introduction
  • 7.1.4 F Hoffmann La Roche Ltd Response to COVID-19 and Related Developments
• 7.2 Orexigen Therapeutics
  • 7.2.1 Orexigen Therapeutics Business Overview
  • 7.2.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020
  • 7.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Introduction
  • 7.2.4 Orexigen Therapeutics Response to COVID-19 and Related Developments
• 7.3 Novo Nordisk A/s
  • 7.3.1 Novo Nordisk A/s Business Overview
  • 7.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020
  • 7.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Introduction
  • 7.3.4 Novo Nordisk A/s Response to COVID-19 and Related Developments
• 7.4 Arena Pharmaceuticals
  • 7.4.1 Arena Pharmaceuticals Business Overview
  • 7.4.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020
  • 7.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Introduction
  • 7.4.4 Arena Pharmaceuticals Response to COVID-19 and Related Developments
• 7.5 Glaxosmithkline
  • 7.5.1 Glaxosmithkline Business Overview
  • 7.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020
  • 7.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Product Introduction
  • 7.5.4 Glaxosmithkline Response to COVID-19 and Related Developments
• 7.6 Vivus
  • 7.6.1 Vivus Business Overview
  • 7.6.2 Vivus Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020
  • 7.6.3 Vivus Anti-Obesity Prescription Drugs Product Introduction
  • 7.6.4 Vivus Response to COVID-19 and Related Developments
• 7.7 Boehringer Ingelheim
  • 7.7.1 Boehringer Ingelheim Business Overview
  • 7.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020
  • 7.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Introduction
  • 7.7.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
• 7.8 Alizyme
  • 7.8.1 Alizyme Business Overview
  • 7.8.2 Alizyme Anti-Obesity Prescription Drugs Quarterly Production and Revenue, 2020
  • 7.8.3 Alizyme Anti-Obesity Prescription Drugs Product Introduction
  • 7.8.4 Alizyme Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Anti-Obesity Prescription Drugs Supply Chain Analysis
  • 8.1.1 Anti-Obesity Prescription Drugs Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Anti-Obesity Prescription Drugs Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Anti-Obesity Prescription Drugs Distribution Channels
  • 8.2.2 Covid-19 Impact on Anti-Obesity Prescription Drugs Distribution Channels
  • 8.2.3 Anti-Obesity Prescription Drugs Distributors
• 8.3 Anti-Obesity Prescription Drugs Customers

9 Key Findings

10 Appendix

• 10.1 About Us